Hopec Pharma is transforming Non-Muscle Invasive Bladder Cancer (NMIBC) treatment with UPEC-FimON, an innovative immunotherapy.

This genetically modified Uropathogenic E. coli triggers targeted immune responses, offering higher efficacy, fewer side effects, and a scalable alternative to Bacillus Calmette-Guérin (BCG).

Designed with cost-effective production, UPEC-FimON ensures that advanced cancer care remains accessible to patients worldwide, addressing the challenges of BCG shortages.Founded by Gadi Klarsfeld and Estee Rosen in 2023, Hopec Pharma leverages over 60 years of experience in pharmaceutical leadership.

Our team is led by Dr.

Ilan Winkler, VP of Drug Development, with guidance from top scientific experts including Prof.

Ofer Mandelboim (immunotherapy), Prof.

Gilad Bachrach (bacterio-oncology), Prof.

Chamutal Gur (NK cells), and Dr.

Vladimir Yutkin, Director of Urologic Oncology at Hadassah Hospital.Following outstanding preclinical results, we will launch Phase 1/2a clinical trials at Hadassah and Sheba hospitals in Q2 2025.

Our robust IP strategy has secured patents across the U.S., Europe, and China, with plans to expand our portfolio and protect future developments.With the global NMIBC market projected to reach $8.6 billion by 2032, Hopec Pharma is positioned to capture significant market share by focusing initially on high-grade patients.

We are actively raising funds to support clinical trials, further expanding our research capabilities, and bringing innovative therapies to market.At Hopec Pharma, we are committed to delivering cutting-edge, accessible treatments that offer new hope and improve patients’ quality of life.